Seongjoon Koo

National Cancer Centre Singapore — Singapore

Biochemistry, Genetics and Molecular Biology · Life Sciences

11h-index2.4kcitations67works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA and Nucleic Acid Chemistry(21), Microtubule and mitosis dynamics(16), Renal and related cancers(15), Renal cell carcinoma treatment(13), Genetics, Bioinformatics, and Biomedical Research(11)

Publications67 total

205P Large language models in clinical oncology: Comparative analysis of colorectal cancer recurrence identification
ESMO Real World Data and Digital Oncology·2025Open Access
2334P The association of socioeconomic status with overall survival in colorectal cancer: A systematic review & meta-analysis
Annals of Oncology·2025
49P A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer
Annals of Oncology·2025Open Access
77P Survival outcomes and molecular characteristics of early-onset colorectal cancer patients (EOCRC): A multiracial cohort
Annals of Oncology·2025Open Access
206P Characterisation of tumour-infiltrating lymphocytes (TILs) in liver metastases (LM) and primary tumour (PT) of microsatellite stable (MSS) colorectal cancers
Immuno-Oncology Technology·2024Open Access
Supplementary Table S6 from Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma
2023Open Access
Supplementary Figure 4a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3a from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3d from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 1a and 1b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Materials from Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma
2023Open Access
Supplementary Figure 2b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Materials from Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma
2023Open Access
Supplementary Table S4 from Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma
2023Open Access
Supplementary Figure 4b from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Supplementary Figure 3c from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Data from Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma
2023Open Access
Supplementary Figure S4 from Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma
2023Open Access
Data from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
Data from Use of a Chemically Modified Antisense Oligonucleotide Library to Identify and Validate Eg5 (Kinesin-Like 1) as a Target for Antineoplastic Drug Development
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Nicholas M. Dean(19), Joseph Riss(15), Chand Khanna(15), Gadisetti V.R. Chandramouli(15), Howard H. Yang(15), David E. Kleiner(15), Carl F. Schaefer(15), Shmuel A. Ben‐Sasson(15), David W. Kane(15), Robert A. Star(15), Olga Aprelikova(15), Kristin Bauer(15), James R. Vasselli(15), Jodi K. Maranchie(15), Kurt W. Kohn(15), Ken H. Buetow(15), John N. Weinstein(15), Maxwell P. Lee(15), Richard D. Klausner(15), Erich Koller(15)